FSD Pharma Inc.

HUGE

CA35954B4047

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 12:58:49 2024-07-17 pm EDT			5-day change	1st Jan Change
0.205 ^CAD	0.00%		+5.13%	-82.92%

Jun. 28	FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	MT
Jun. 28	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT

FSD Pharma Inc. authorizes a Buyback Plan.

January 12, 2023

The Board of Directors of FSD Pharma Inc. has authorized a buyback plan on January 13, 2023.

Latest news about FSD Pharma Inc.

FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
Sector Update: Health Care Stocks Decline in Late Afternoon Trading	Jun. 28	MT
FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
FSD Pharma Inc. announced that it has received CAD 0.195 million in funding	Jun. 27	CI
FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia	Jun. 27	CI
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	Jun. 04	CI
FSD Pharma Slightly Lower In US Premarket As Submits Clinical Trial Protocol to Study Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	May. 28	MT
FSD Pharma Inc. Submits A Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	May. 28	CI
FSD Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia	May. 07	CI
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	Apr. 30	CI
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	Apr. 25	MT
FSD Pharma Receives Nasdaq Non-Compliance Notice	Apr. 08	MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	Mar. 27	MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	Mar. 27	MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	Mar. 11	MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	Mar. 11	CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	Mar. 05	MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	Mar. 05	MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	Mar. 05	CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma	Feb. 19	MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	Feb. 06	MT

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FSD PHARMA INC.	-82.92%	7.15M
VERTEX PHARMACEUTICALS INCORPORATED	+20.34%	126B
REGENERON PHARMACEUTICALS, INC.	+22.98%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.64%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-13.60%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+10.33%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+51.69%	14.08B